Jessica Herzig/LinkedIn
Dec 21, 2025, 13:54
Jessica Herzig on CD86 Expression Correlation with Immune Cell Activation
RPTH Journal shared on LinkedIn:
”Why do some hemophilia A patients develop inhibitors?
This study points to immune activation patterns that depend more on timing, even seasonality, than on the FVIII product itself.
Check out this fascinating study by Jessica Herzig and team here.”
Article: Season-dependent low basal CD86 expression promotes immune cell activation upon treatment with plasma-derived factor Ⅷ products
Authors: Jessica Herzig, Josselyn Azucena Arciniega Martinez, Svenja M. Küster, Eva Ringler, Stefanie Kronhart, Gerrit J. K. Praefcke, Lilija Miller, Martina Anzaghe, Zoe Waibler
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC